Compounded semaglutide and compounded tirzepatide injection · Last updated September 15, 2026
Summarized from the Drug Interactions section of the FDA-approved prescribing information for Wegovy® and Zepbound®. This page has not yet been clinically reviewed.
Both labels have a Drug Interactions section, and between them it covers two things: medications that lower blood sugar, and medications you swallow. Everything on this page comes from those sections, or from a section they point at — the tirzepatide label states the hypoglycemia risk itself in its Warnings, §5.7, and its Drug Interactions section cross-references it.
These are the labels for Wegovy® and Zepbound® — the FDA-approved products. What Leland’s partner pharmacies prepare is compounded semaglutide and compounded tirzepatide, which are not FDA-approved and were not the products these trials studied. The labels are the best evidence there is about how these molecules behave; they are not evidence about a compounded preparation at a dose the trials did not test.
That makes this a short page, and the shortness is the point — a labeled interaction is one the manufacturer had to document. A medication not named here has not been cleared; it has not been addressed. Your prescriber and your pharmacist have your full list, and they are the ones who can weigh it.
This is the interaction both labels lead with, and the only one either of them attaches a dosing instruction to.
Semaglutide and tirzepatide
GLP-1 medications lower blood glucose. Taken with insulin or an insulin secretagogue — the sulfonylurea class — the risk of hypoglycemia goes up. Both labels direct the prescriber to consider reducing the dose of the insulin or secretagogue when GLP-1 treatment is started. That is a decision for the clinician who prescribes them, not one to make on your own.
Wegovy §7.1; Zepbound §7.1 and §5.7
Semaglutide only
The semaglutide label states that its addition in patients already treated with insulin has not been evaluated. The tirzepatide label makes no equivalent statement. Not evaluated is not the same as unsafe — it means the trials did not answer the question, and your prescriber is deciding without that answer.
Wegovy §7.1; absent from Zepbound §7
Both medications slow how fast the stomach empties. That is part of how they work, and it is also why the labels address anything taken by mouth.
Semaglutide and tirzepatide
Both labels say the delay in gastric emptying has the potential to affect the absorption of oral medications taken at the same time, and both direct extra monitoring for medications with a narrow therapeutic index — drugs where the difference between too little and too much is small.
Wegovy §7.2; Zepbound §7.2
Tirzepatide only
The tirzepatide label gives warfarin as its example of a narrow-therapeutic-index medication, and adds medications that depend on reaching a threshold concentration to work.
Zepbound §7.2
Semaglutide only
The potential and the measurement are different things, and the semaglutide label reports both. In clinical pharmacology trials, semaglutide 1 mg once-weekly injection did not affect the absorption of orally administered medications — that is the dose that was studied, not every dose. A separate study of the semaglutide tablet — a different product, taken by mouth — found levothyroxine exposure increased by 33%. The label still directs monitoring the effects of oral medications taken alongside it.
Wegovy §7.2
Tirzepatide only
The tirzepatide label advises anyone using an oral hormonal contraceptive to switch to a non-oral method, or to add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. The label says hormonal contraceptives that are not taken by mouth should not be affected — its hedge, kept here, not a clearance. The semaglutide label carries no contraceptive advice of any kind, so this instruction belongs to tirzepatide alone.
Zepbound §7.2; absent from Wegovy §7
A page answering "can I take this with X" is not a lookup against a list. For most medications the labels say nothing, so answering means reasoning from how both drugs behave to a conclusion about one person — which is the judgment a prescriber is licensed to make and this website is not.
This site has no clinician who has reviewed such pages, so publishing them would mean publishing confident answers nobody qualified had checked. A missing page sends you to your prescriber. A wrong page stops you from going.
Bring your full list — prescriptions, over-the-counter medicines, and supplements — to the clinician who would prescribe treatment. That review is part of the intake, and it is the one that accounts for your medications rather than medications in general.
This page summarizes what the two prescribing informations address. It is not a complete list of interactions, and it does not describe how these medications would act alongside yours. Do not start, stop or change a medication based on it.
Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.